Research conducted on rat models with induced colitis shows a reduction in intestinal damage markers following BPC-157 administration
J Sci Med Sport 19(3):200204 Kikuchi N, Yoshioka T, Taniguchi Y, Sugaya H, Arai N, Kanamori A, Yamazaki M (2019) Optimization of leukocyte-poor platelet-rich plasma preparation: a validation study of leukocyte-poor platelet-rich plasma obtained using different preparer, storage, and activation methods
We primarily recommend Vitamin B12 injections for patients with conditions that impede B12 absorption, such as pernicious anemia, gastrectomy, Crohns disease, or Vitamin B12 malabsorption
KPV may be most relevant if you: Have a confirmed diagnosis of Crohn's disease or ulcerative colitis and are seeking adjunct anti-inflammatory support Manage a chronic inflammatory skin condition (eczema, psoriasis, atopic dermatitis) with incomplete response to standard treatments Have elevated systemic inflammatory markers alongside gut symptoms Are managing Mast Cell Activation Syndrome and looking for targeted cytokine modulation Have had adverse reactions to systemic immunosuppressants and need an alternative with a different mechanism KPV is likely not the right starting point if: You primarily need tissue repair rather than inflammation control (BPC-157 may be a better fit for structural gut repair) You have no active inflammatory diagnosis You are seeking peptide therapy without medical supervision Safety Profile and Limitations of the Current Evidence KPV has demonstrated a favorable safety profile in preclinical research no significant toxicity signals have emerged across two decades of animal studies
